Description:

Atara Biotherapeutics, Inc. (ATRA), listed on the New York Stock Exchange, is a pioneering biopharmaceutical company focused on developing novel treatments for patients with severe and life-threatening diseases. Atara's innovative approach centers around allogeneic T-cell immunotherapies, which are designed to harness the power of the immune system to combat diseases such as Epstein-Barr virus (EBV)-driven lymphomas and multiple sclerosis. The company's pipeline includes several clinical-stage programs aimed at addressing unmet medical needs in oncology and autoimmune disorders, positioning Atara as a key player in advancing cell therapy technologies.

Data:

Yields: